 Breast cancer is the second most common cause of brain metastases. Overall survival after the development of brain metastases tends to be poor 6-8 months. Over-expression of Human Epidermal Growth Factor Receptor 2 HER-2neu, negative estrogen receptor, and young age at diagnosis seem to be indicators of high risk for brain metastases. Temozolomide may be a good candidate for prophylactic chemotherapy because of its ability to cross the blood-brain-barrier, achieving high concentrations in the central nervous system CNS. 